It's really been a powerful tool in molecular biology because I might have a very small copy of a gene that I'm interested in and I can make enough copies that I can start to do something else with it.
"Although I felt encouraged I also realised I need to dosomethingwith my game to make sure I get back where I want to be - in the top 10, " he told his official website.
Getting the most out of medicines that domake it to market will require better relationships with health insurers, something D'Amelio, who has served on the board of insurer Humana, may also be able to help with.